Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-25
1997-09-16
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514214, 514292, 514411, 514414, 540479, 540579, 546 85, 546201, 548428, 548466, A61K 31445, C07D40314
Patent
active
056681526
ABSTRACT:
The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
REFERENCES:
patent: 4785085 (1988-11-01), Kaneko et al.
patent: 4808613 (1989-02-01), Kaneko et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5057614 (1991-10-01), Davis et al.
patent: 5292747 (1994-03-01), Davis et al.
patent: 5380746 (1995-01-01), Barth et al.
Thomas et al. "Dioctanoylglycerol regulation of cytosolic CA by protein kinase C-indipendent mechanism in HIT T-15 islet cells" Diabetes vol. 40, pp. 621-627 (1991) *see copy in copending case SN 08/450,321.
Dominique et al. "The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C" Jo. Biolo. Chem. vol. 266 (24)pp. 15771-15781 (1991).
Derwent Abstract 90-132947/18; 21.10.88-DE-835842.
Derwent Abstract 92-274042/33;90.11.20 90JP-314628.
Meier, et al., Tetrahedron Letter, 34:33, 5277-5280 (1993).
Wilkinson, et al., Bichem. J., 294, 335-337 (1993).
Bit, et al., J. Med. Chem., 36, 21-29 (1993).
Martiny-Baron, et al., The Journal of Biological Chemistry, 268:13, 9194-9197 (1993).
Krakowiak, et al, Synlett, 611-620, (Sep. 1993).
Mulqueen, et al., Agents Actions, 37, 85-89 (1992).
Davis, et al., J. Med. Chem., 35, 177-184 (1992).
Davis, et al., J. Med. Chem., 35, 994-1001 (1992).
Nixon, et al., Drugs Exptl. Clin. Res., 17:8, 389-393 (1991).
Davis, et al., Tetrahedron Letters, 31:36, 5201-5204 (1990).
Brenner, et al., Tetrahedron Letters, 44:10, 2887-2892 (1988).
Joyce, et al., The Journal of Organic Chemistry, 52:7, 1177-1186 (1987).
Buchdunger, et al., Proc. Natl. Acad. Sci. USA, 91, 2334-2338 (Mar. 1994).
Kobayashi, et al., The American Physiological Society, 0363-6135, H1214-H1220 (1994).
Felsenstein, et al., Neuroscience Letters, 174 173-176 (1994).
Demaerschalck, et al., Biochimica et Biophysica Acta, 1181 214-218 (1993).
Shimohama, et al., Neurology, 43 1407-1413 (1993).
Kleinschroth et al. "5,7-dioxo-5H-dindolo[2,3-a]pyrrolo[3,4-c]carbazoles as protein kinase inhibitors . . . " CA 120:270356 1994.
Heath, Jr. William F.
McDonald, III John H.
Ruhter Gerd
Schotten Theo
Boone David E.
Caltrider Steven P.
Chang Ceila
Eli Lilly and Company
LandOfFree
Protein kinase C inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein kinase C inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase C inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-218603